Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Pediatric Solid Tumors
NCT02085148Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of regorafenib in solid tumor, rhabdomyosarcoma (RMS), Ewing sarcoma and 3 more (3 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose at 21 months, Recommended Phase II Dose at 21 months and 2 more. Started Apr 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
solid tumorrhabdomyosarcoma (RMS)Ewing sarcomahepatoblastomaneuroblastoma
Beyond the preview
Go deeper on NCT02085148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085148.